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This study sought to evaluate the eﬃcacy of long-term ﬂecainide therapy in maintaining
sinus rhythms in patients with paroxysmal atrial ﬁbrillation (AF) based on time of onset.
Flecainide (150mg/day) was administered as an antiarrhythmic drug to a total of 70 patients
(54 men and 16 women: mean age 65 10 years) after sinus rhythm was restored
spontaneously or by electrical and/or pharmacological cardioversion. Paroxysmal AF was
divided into three categories based on time of onset: diurnal type (N ¼ 11), nocturnal type
(N ¼ 13), and mixed type (N ¼ 46). The mean follow-up period was 37:7 17:7 months.
The duration of sinus rhythm maintenance in patients with diurnal and nocturnal paroxysmal
AF was 32:4 10:4 months and 20:8 8:3 months, respectively; the duration of sinus
rhythm maintenance in those with mixed paroxysmal AF was only 7:2 2:1 months.
Signiﬁcant diﬀerences were observed in duration between diurnal and mixed cases (mean
S.E., P < 0:05). Actuarial recurrence-free rates at 1, 3, 6, 9 and 12 months were 90.9%,
63.6%, 63.6%, 54.5%, and 54.5%, respectively, for diurnal cases; 84.6%, 76.9%, 53.8%,
38.5%, and 30.8%, respectively, for nocturnal cases; and 58.7%, 39.1%, 28.3%, 21.7%, and
15.2% respectively, for mixed cases. Signiﬁcant diﬀerences in rates at 12 months were
observed between diurnal and mixed cases (P < 0:05). These results suggest that ﬂecainide is
highly eﬀective in preventing AF recurrence in patients with diurnal paroxysmal AF.
(J Arrhythmia 2006; 22: 37–43)
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Introduction
In previous studies, antiarrhythmic drugs for
maintaining sinus rhythm in patients with paroxys-
mal atrial ﬁbrillation (AF) were selected based on
therapeutic eﬃcacy as observed by the trial-and-
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error method or based on the personal experience of
individual physicians. Japan’s rapidly aging popula-
tion (and hence AF morbidity) is expected to
increase gradually but continuously, creating a need
for a drug that prevents AF recurrence with high
eﬃcacy. According to Yamashita et al., paroxysmal
AF, unlike other arrhythmic conditions in humans,
tends to display speciﬁc circadian variations in
patients,1) allowing for an eﬃcient therapeutic
strategy based on the mechanism of initiation of
paroxysmal AF employing a reasonable selection of
antiarrhythmic drugs. Previously we discussed the
eﬃcacy of disopyramide,2) cibenzoline,3) and pilsi-
cainide4) in preventing AF recurrence based on time
of onset of paroxysmal AF, demonstrating that the
selection of antiarrhythmic drugs based on time of
onset could enhance therapeutic eﬃcacy in prevent-
ing AF recurrence. In the present study, we eval-
uated the long-term eﬃcacy of ﬂecainide based on
time of onset of arrhythmia to maintain sinus rhythm
in patients with paroxysmal AF, exploring whether
the time of onset of arrhythmia could be used as a
parameter in choosing ﬂecainide treatment.
Subjects
Performed from June, 1997 to October, 2003, the
study involved 70 patients with symptomatic parox-
ysmal AF (54 men and 16 women, aged from 32 to
84; mean age 65 10 years) regarded as needing
antiarrhythmic drug therapy (AAT) due to the
severity of their symptoms. All patients underwent
follow-up examinations once or twice a month at the
Iwate Prefectural Iwai Hospital outpatient clinic. The
examination at each visit assessed whether sinus
rhythm was maintained without AF recurrence or
whether AF had recurred, based on symptoms and
ECG ﬁndings. Ambulatory 24-hour ECG recordings
were repeated at 3-month intervals or when consid-
ered necessary by the physician. Pharmacological
and/or electrical cardioversion was applied if AF
recurred and did not terminate spontaneously. The
mean duration of paroxysmal AF at hospital visits in
the present study was 41:6 110:5 hours, ranging
from 2.3 hours to 7 days. The mean follow-up period
was 37:7 17:7 months, (mean  one standard
deviation; range 12 to 84) for all patients. All
patients underwent chest X-ray examination, ECG
recording, exercise ECG testing, echocardiography,
and head CT scans before initiation of antiarrhyth-
mic therapy. Eighteen patients had underlying heart
diseases such as coronary artery disease (10 pa-
tients), valvular heart disease (3), hypertrophic
cardiomyopathy (3), dilated cardiomyopathy (1), or
cardiac syndrome X (1). Seven patients had pulmo-
nary diseases such as healed tuberculosis (4 pa-
tients), bronchial asthma (2), and pulmonary em-
physema (1). The study excluded patients taking
beta-blockers or having congestive heart failure, left
ventricular ejection fraction <40% as determined by
echocardiography, bradycardias <40 beats/minute,
duration of AF morbidity =7 days, severe intra-
ventricular conduction disturbances, severe liver or
renal dysfunctions, or other serious complications.
A total of 70 patients were divided into three
subcategories, according to the time of onset of
paroxysmal AF: diurnal type (11 patients), nocturnal
type (13 patients), and mixed type (46 patients), and
the eﬃcacy of ﬂecainide was compared among the
three groups. The diurnal type was deﬁned as AF
occurring only during daytime between 7 a.m. and
5 p.m., whereas the nocturnal type was deﬁned as AF
occurring only during nighttime from 5 p.m. to 7 a.m.
The mixed type was deﬁned as AF occurring during
both daytime and nighttime.2–4)
Before antiarrhythmic drug therapy, ambulatory
24-hour ECG recordings were performed 1:4 0:4
times in patients with diurnal type paroxysmal AF,
1:3 0:3 times in those with nocturnal type parox-
ysmal AF, and 1:5 0:3 times in those with mixed
type paroxysmal AF. No signiﬁcant diﬀerences in
the frequency of examination recorded by ambula-
tory 24-hour ECG among the three groups were
observed.
Protocols of Antiarrhythmic Drug Therapy
After restoration of sinus rhythms spontaneously
or by cardioversion, one of three class-I drugs—
disopyramide (300mg/day), cibenzoline (300mg/
day), or aprindine (60mg/day)—was selected by the
envelope method and was administered orally as
initial drug therapy. When AF recurred, sinus rhythm
was restored, and one of three drugs—ﬂecainide
(150mg/day), pilsicainide (150mg/day), or bepridil
(150mg/day)—was selected by the envelope meth-
od. As to administration, a 50-mg tablet of ﬂecainide
was administered orally three times daily after each
meal. The recurrence-free rates of patients treated
with ﬂecainide after AF recurrence refractory to
initial drug therapy were then analyzed in this study.
Deﬁnition and Statistical Analysis
Paroxysmal AF was deﬁned as AF terminating
spontaneously within 7 days after occurrence. Dura-
tion of AF morbidity was deﬁned as the period from
the initial episode of paroxysmal AF to the initiation
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of AAT. Hypertension was deﬁned as systolic and
diastolic blood pressures greater than 160mmHg and
90mmHg, respectively.5)
Data were shown as mean plus or minus one
standard deviation, while data for duration of sinus
rhythms were shown as mean plus or minus one
standard error. Clinical proﬁles of patients among
the three groups were compared using one-way
ANOVA for continuous variables and the Chi-square
test for categorical variables. Survival curves were
estimated by the Kaplan and Meier method and
compared by the log-rank test. P < 0:05 was
considered to indicate statistical signiﬁcance.
Results
1. Comparisons of Clinical Characteristics
No signiﬁcant diﬀerences were observed among
the three groups with respect to age, gender, body
weight, percentage of patients with coronary risk
factors, and percentage of patients treated with
angiotensin-converting enzyme inhibitors or angio-
tensin-receptor blockers. No signiﬁcant diﬀerences
were observed among the three groups in AF
duration and morbidity, distributions of underlying
heart and pulmonary disease, end-diastolic left
ventricular dimensions, left atrial dimensions, and
left ventricular ejection fractions, as determined by
echocardiography. Finally, no signiﬁcant diﬀerences
were observed among the three groups in mean heart
rate or systolic and diastolic blood pressure during
AF. Plasma concentrations of human atrial natriu-
retic polypeptides (HANP) during sinus rhythms in
the mixed group were greater than those in the
diurnal and nocturnal groups (P < 0:05, Table 1).
2. Comparison of AF Recurrence Prevention in
Patients Treated with Flecainide
As shown in Figure 1, the actuarial recurrence-free
rates of patients treated with ﬂecainide therapy at 1,
3, 6, 9, and 12 months were, respectively, 90.9%,
63.6%, 63.6%, 54.5%, and 54.5% in the diurnal
group; 84.6%, 76.9%, 53.8%, 38.5%, and 30.8% in
the nocturnal group; and 58.7%, 39.1%, 28.3%,
Table 1 Comparison of clinical characteristics among patients with paroxysmal atrial ﬁbrillation.
Diurnal type Nocturnal type Mixed type P-value
Number 11 13 46
Age 65 11 64 14 66 9 N.S.
Male:female 8:3 12:1 34:12 N.S.
Smoking 3(27%) 6(46%) 15(33%) N.S.
Hypertension 5(46%) 2(15%) 19(41%) N.S.
Diabetes mellitus 3(27%) 2(15%) 12(26%) N.S.
Hyperlipidemia 2(18%) 2(15%) 6(13%) N.S.
Hyperuricemia 0(0%) 1(8%) 2(4%) N.S.
Alcohol 3(27%) 8(62%) 24(52%) N.S.
Body weight (Kg) 57 8 58 9 59 8 N.S.
ACE-I or ARB 3(27%) 2(15%) 10(22%) N.S.
Follow-up period (months) 39 22 37 17 36 15 N.S.
OHD 3(27%) 3(23%) 12(26%) N.S.
OPD 2(18%) 2(15%) 3(7%) N.S.
AF duration (hours) 33 94 40 109 52 120 N.S.
AF morbidity (months) 29 27 42 75 35 50 N.S.
LVDd (mm) 49 3 46 3 46 7 N.S.
LAD (mm) 36 6 32 6 35 7 N.S.
LVEF (%) 70 12 72 7 67 14 N.S.
Mean heart rate (bpm) 112 31 108 28 111 24 N.S.
Systolic blood pressure (mmHg) 129 16 123 14 126 12 N.S.
Diastolic blood pressure (mmHg) 82 12 80 11 81 10 N.S.
HANP during SR (pg/ml) 25 12 28 24 56 51 P < 0.05
P < 0:05; Diurnal type, Nocturnal type vs Mixed type. ACE-I: Angiotensin-converting enzyme inhibitors, ARB:
Angiotensin-receptor blockers, OHD: Organic heart disease, OPD: Organic pulmonary disease, LVDd: Left ventricular
end-diastolic dimension, LAD: Left atrial dimension, LVEF: Left ventricular ejection fraction, HANP: Human atrial
naturiuretic peptide, AF: Atrial ﬁbrillation, SR: Sinus rhythm
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21.7%, and 15.2% in the mixed group. At 12 months,
recurrence-free rates for diurnal cases were signiﬁ-
cantly higher than these rates for mixed cases
(P < 0:05). Periods of sinus rhythm maintenance
when treated with ﬂecainide therapy were 32:4
10:4 months for diurnal cases, 20:8 8:3 months for
nocturnal cases, and 7:2 2:1 months for mixed
cases. The period for the diurnal group was
signiﬁcantly greater than that for the mixed group
(P < 0:05) (Figure 2).
Discussion
According to the classiﬁcation of antiarrhythmic
drugs proposed under the so-called Sicilian Gam-
bit,6) the major pharmacological action of ﬂecainide
on single cardiac myocytes is regarded to be the
blocking of sodium and potassium currents. With its
sodium-channel inhibition properties, ﬂecainide is
classiﬁed as a slow kinetic drug due to diﬀerences in
recovery relative to use-dependent blocks, and is
expected to have inhibitory eﬀects due to its
relatively high accumulation. Flecainide has an
aﬃnity for the activated phase during depolarization
and is not seriously aﬀected by the duration of action
potentials, as linkages between drug and receptors
are formed in the emerging phase of the action
potential; further, it is considered as acting in atrial
muscle, which has a short action-potential plateau
phase.7) In Japan, slow kinetic sodium-current block-
ers such as ﬂecainide are currently administered to
patients with paroxysmal AF to maintain sinus
rhythm.8) As for the pharmacological actions of
ﬂecainide with respect to potassium currents, the
blockade of voltage-dependent IKr and Ito, ligand-
dependent IkATP, and IKACh currents have all been
reported.6,9) However, based on the Sicilian Gambit
classiﬁcation, the pharmacological actions of ﬂecai-
nide at the recommended doses are evaluated as less
potent in inhibiting potassium currents than in
inhibiting sodium currents.6) Flecainide is considered
to prolong the eﬀective refractory period and intra-
atrial conduction in the human atrial myocardium.10)
Reports from Europe and the U.S. indicate varying
eﬃcacy in preventing AF recurrence among patients
treated with ﬂecainide. Previous reports put the
recurrence-free rates for those treated with ﬂecainide
from 31% to 61% at several months, from 60% to
63% at 6 months, and from 62% to 72% at 12
months.11–19) We have also examined the eﬃcacy of
ﬂecainide in preventing AF recurrence among
patients who demonstrated repeated AF recurrence
despite class-Ia or -Ib antiarrhythmic drugs therapy,
reporting actuarial recurrence-free rates of 33% and
30% at 12 months and 24 months,20) respectively.
Our data were considered to reﬂect values lower than
those previously reported in Europe and the U.S.
Such diﬀerences in recurrence-free rates may depend
on patient clinical proﬁles; in our study, only half of
the patients resistant to the ﬁrst antiarrhythmic drug
were free of AF recurrence after ﬂecainide therapy.
In Europe and the U.S., the eﬃcacy of antiarrhyth-
mic drugs was evaluated using doses higher by a
factor of 1.5 to 2 times relative to doses used in
Japan. Thus, the results obtained overseas are not
perfectly comparable to those obtained in Japan. In
previous studies, however, there has been little
information on individualized selection of antiar-
rhythmic drugs to maintain sinus rhythms in patients
with paroxysmal AF.
The present study classiﬁed paroxysmal AF cases
as one of three types based on time of onset—
diurnal, nocturnal, and mixed—and compared the
eﬃcacy of ﬂecainide among patients assigned to one
of the three categories. Also, a 50-mg tablet of
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Figure 1 Actuarial recurrence-free rates among the three
groups after ﬂecainide therapy.
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Figure 2 Periods of sinus-rhythm maintenance among the
three groups after ﬂecainide therapy.
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ﬂecainide was administered orally three times daily
after each meal to even out the serous concentration
of ﬂecainide over the course of the day. At 12
months after ﬂecainide therapy, patients with diurnal
AF showed a 54.5% recurrence-free rate, while
patients with nocturnal or mixed AF showed recur-
rence-free rates of only 30.8% and 15.2%, respec-
tively. This indicated that ﬂecainide can serve as one
of the ﬁrst-line drugs for patients with diurnal
paroxysmal AF when no contraindications are
present.
Paroxysmal AF is believed to be caused by intra-
atrial random reentry induced by supraventricular
extrasystole originating from the pulmonary vein,
mostly due to triggered activity.21) In fact, the
prevalence of extrasystole that induces paroxysmal
AF has not been fully elucidated. However, based on
the assumption that the onset of diurnal-type atrial
ﬁbrillation is closely related to extrasystole induced
by sympathetic hypertonia, a Na-channel blocker
such as ﬂecainide should suppress such extrasystole.
Further, sympathetic hypertonia not only activates
the Na channel via the 1-receptor, but also induces
intracellular Ca overload via the sarcoplasmic
reticulum Ca-pump to induce arrhythmia by trig-
gered activity.22) In other words, a Na-channel
blocker may also suppress arrhythmia induced by
sympathetic hypertonia.
Since 1 receptors activated by sympathetic
hypertonia can enhance sodium currents when
myocardial membrane potential is reduced,23) block-
ading sodium currents may also inhibit supraven-
tricular extrasystole in patients with diurnal AF.
According to reports on the activity of the autonomic
nervous system based on analysis of the heart-rate
variability spectrum, ﬂecainide was found to reduce
activity in the low frequency band (LF), which is
closely associated with sympathetic hypertonia.24,25)
Such data suggest that ﬂecainide may be especially
eﬀective in preventing recurrence of paroxysmal AF
in patients with diurnal AF in whom AF occurs
predominantly during the daytime. In our previous
study,4) pilsicainide, a pure sodium-channel blocker,
was shown to be eﬀective in preventing recurrence
of paroxysmal AF in patients with diurnal AF, based
on analysis at the time of arrhythmic onset. Not only
combination therapy with -blockers, but also
sodium-channel blocker monotherapy may be ex-
tremely useful for maintaining sinus rhythm in
patients with diurnal AF.
The present study accounted for potential dif-
ferences in patient characteristics among the three
groups before comparisons of ﬂecainide preventive
eﬃcacy, since age,26) left atrial dimensions,27) under-
lying heart disease,28) and duration of AF morbid-
ity29) have all been found to aﬀect the eﬃcacy of
AAT in preventing the recurrence of paroxysmal AF.
This study found no signiﬁcant diﬀerences in patient
characteristics among the three groups, including
those characteristics aﬀecting AAT eﬃcacy. How-
ever, the mean follow-up period was approximately
36 months in the present study, while the mean
follow-up periods in most earlier studies reported in
Europe and the U.S. have generally been shorter
(ranging from one to nine months).11–19) Given the
serious complications arising in patients with parox-
ysmal AF, such as thromboembolism or heart failure,
evaluating the eﬃcacy of AAT for long-term follow-
up periods appears appropriate.18,19)
Limitation
In the present study, grouping of ﬂecainide
administration was random and prospective, whereas
recurrence-free rates were analyzed retrospectively
in patients with paroxysmal AF who were classiﬁed
into three groups based on the time of onset. Diurnal
type cases were deﬁned as patients who had episodes
of paroxysmal AF only during the daytime, noctur-
nal cases as those who had episodes of paroxysmal
AF only during the nighttime, and mixed cases as
those who had episodes of paroxysmal AF occurring
irrespective of circadian variations. However, to
conﬁrm the validity of a system of classiﬁcation
based on the time of onset, we must clarify the close
relationship between diurnal type AF and sympa-
thetic hypertonia, and that between nocturnal type
AF and parasympathetic hypertonia, through analy-
sis of the heart-rate variation spectrum.30,31) In
addition, the frequency of examination recorded by
ambulatory 24-hour ECG without antiarrhythmic
drugs was only an average of 1.4, and therefore an
event of AF recurrence in all patients was not
examined fully in relation to the time of onset in the
present study. Also, the number of cases in the
present study was low, and further investigations
involving the study of additional cases will be
necessary. Page et al. have reported that in patients
with paroxysmal AF, sustained asymptomatic AF
occurs far more frequently than symptomatic AF.32)
In the present study, all patients were diagnosed as
free of AF recurrence based on symptoms and ECG
ﬁndings assessed once or twice a month at the
outpatient clinic. However, the possibility of the
occurrence of asymptomatic AF episodes in these
patients cannot be ruled out, due to methodological
limitations in identifying episodes of AF recurrence
after AAT based on symptoms or ECG ﬁndings.
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Furthermore, when selecting drugs to prevent re-
currence of paroxysmal AF, in cases where onset is
closely related to exertion or psychological tension,
-blockers are generally selected rather than class-I
antiarrhythmic drugs such as ﬂecainide.
Conclusion
We found that ﬂecainide showed higher eﬃcacy
in the long-term prevention of AF recurrence in
patients with diurnal type AF, in whom AF occurred
only during the daytime.
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